Jubilant Ingrevia Limited is a global player in Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates, serving diverse sectors like Pharmaceuticals, Agrochemicals, Nutrition, and Consumer products.

The company reported an 8% year-over-year increase in EBITDA for Q2 FY26 and a substantial 18% rise in Profit After Tax, demonstrating its ability to enhance profitability amidst challenging market conditions. Steady volume growth was seen across its segments.

In the Specialty Chemicals segment, the company is capitalizing on CDMO opportunities with 10+ new molecules added recently and advanced discussions for others. This segment's margins are robust, over 25%, due to strong client traction and cost strategies.

The Nutrition and Health Solutions business faced pricing pressures but countered them through volume growth and its strategic pipeline of EU Choline advantages following anti-dumping duties. Despite competitive pricing pressures, growth opportunities are leveraged.

Jubilant Ingrevia's global manufacturing capabilities across multiple sites in India, including recent expansions at its facilities, reinforce its broad product offerings. The new Multipurpose Plant (MPP) at Gajraula will support future growth in its core business areas.